Salk team prepares to test monthly antifertility drug
- PMID: 12276554
Item in Clipboard
Salk team prepares to test monthly antifertility drug
Med Trib Med News.
.
Abstract
PIP: Scientists from the Salk Institute and the University of California will soon test the use of a once-a-month antifertility drug on women. Composed of peptides, the antifertility agents antagonize the normal action of luteinizing hormone-releasing factors (LRF), inhibiting the secretion of luteinizing hormone (LH) by the pituitary. Administration should begin within the first 10 days of the menstrual cycle to be effective.
Similar articles
-
Production of anti luteinizing hormone releasing factor (LH-RF) serum: immunological application and development of radioimmunoassay.Nihon Funin Gakkai Zasshi. 1976 Oct;21(4):12-21. Nihon Funin Gakkai Zasshi. 1976. PMID: 12158548
-
Luteinizing hormone releasing factor activity in peripheral blood from women during the midcycle luteinizing hormone ovulatory surge.J Clin Endocrinol. 1972;34:271-8. J Clin Endocrinol. 1972. PMID: 12256659
-
New contraceptives tested for women and men.Res Resour Rep. 1983 May;7(5):1-4. Res Resour Rep. 1983. PMID: 12338626
-
Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.Contracept Deliv Syst. 1983 Apr;4(2):107-25. Contracept Deliv Syst. 1983. PMID: 12338631
-
[Effects of LH-RH analogue on hormonal levels of normal women in the early follicular phase].Shengzhi Yu Biyun. 1983 Aug;3(3):62. Shengzhi Yu Biyun. 1983. PMID: 12267403 Chinese.